A systematic approach for successful PCSK9 inhibitor prescribing in clinical practice

Thomas Knickelbine, Lori Jia, Susan K. White, Ross F. Garberich, Sandra J. Oberembt, Samantha Wills, Michael D. Miedema, Emmanouil S Brilakis

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Despite patient and provider interest, the use of PCSK9i therapy remains limited in clinical practice. High annual listed prices have created intense payer scrutiny and frequent health plan denials, with national approval rates in the range of 30% to 40%. Objective: Our goal was to validate the strategies for increasing PCSK9i approval rates and to present a framework for successful PCSK9i prescribing in clinical practice. Methods: In Sept 2015, a systematic team-based approach was developed and implemented at our institution. The approach centered on a preventive team of 3 senior staff cardiologists, 1 nurse practitioner, 1 physician assistant, 1 care coordinator, 1 pharmacist, and 1 pharmacy technician. The team was responsible for gathering and compiling the required documents to support an approval, as well as collaborating with the in-house pharmacy to complete PA and appeals processes. Results: In the total study population, 141 (71.9%) were approved for PCSK9i therapy at first submission and 55 (28.1%) were rejected. Of those initially rejected, 48 (85.7%) appealed and all 48 who appealed (100.0%) were ultimately approved. The final coverage decision was 189 (96.4%) approved and 7 (3.6%) rejected. Conclusion: Our study highlights the presence of modifiable barriers in the PCSK9i approval process. Given the crucial role of health care teams in overcoming these modifiable barriers, we developed a simple stepwise algorithm for navigating the PCSK9i approval process. Our algorithm can help relieve busy providers of heavy administrative burdens and facilitate greater accuracy, standardization, and efficiency in documentation.

Original languageEnglish (US)
JournalJournal of Clinical Lipidology
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Physician Assistants
Patient Care Team
Nurse Practitioners
Pharmacists
Documentation
Health
Therapeutics
Population
Pharmacy Technicians
Cardiologists

Keywords

  • Alirocumab (Praluent)
  • Atherosclerotic cardiovascular disease (ASCVD)
  • Evolocumab (Repatha)
  • Familial hypercholesterolemia (FH)
  • Low-density lipoprotein cholesterol (LDL-C)
  • Prior authorization

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine

Cite this

A systematic approach for successful PCSK9 inhibitor prescribing in clinical practice. / Knickelbine, Thomas; Jia, Lori; White, Susan K.; Garberich, Ross F.; Oberembt, Sandra J.; Wills, Samantha; Miedema, Michael D.; Brilakis, Emmanouil S.

In: Journal of Clinical Lipidology, 01.01.2019.

Research output: Contribution to journalArticle

Knickelbine, Thomas ; Jia, Lori ; White, Susan K. ; Garberich, Ross F. ; Oberembt, Sandra J. ; Wills, Samantha ; Miedema, Michael D. ; Brilakis, Emmanouil S. / A systematic approach for successful PCSK9 inhibitor prescribing in clinical practice. In: Journal of Clinical Lipidology. 2019.
@article{5d58f50015f84ba19b7cb2aaf87d3314,
title = "A systematic approach for successful PCSK9 inhibitor prescribing in clinical practice",
abstract = "Background: Despite patient and provider interest, the use of PCSK9i therapy remains limited in clinical practice. High annual listed prices have created intense payer scrutiny and frequent health plan denials, with national approval rates in the range of 30{\%} to 40{\%}. Objective: Our goal was to validate the strategies for increasing PCSK9i approval rates and to present a framework for successful PCSK9i prescribing in clinical practice. Methods: In Sept 2015, a systematic team-based approach was developed and implemented at our institution. The approach centered on a preventive team of 3 senior staff cardiologists, 1 nurse practitioner, 1 physician assistant, 1 care coordinator, 1 pharmacist, and 1 pharmacy technician. The team was responsible for gathering and compiling the required documents to support an approval, as well as collaborating with the in-house pharmacy to complete PA and appeals processes. Results: In the total study population, 141 (71.9{\%}) were approved for PCSK9i therapy at first submission and 55 (28.1{\%}) were rejected. Of those initially rejected, 48 (85.7{\%}) appealed and all 48 who appealed (100.0{\%}) were ultimately approved. The final coverage decision was 189 (96.4{\%}) approved and 7 (3.6{\%}) rejected. Conclusion: Our study highlights the presence of modifiable barriers in the PCSK9i approval process. Given the crucial role of health care teams in overcoming these modifiable barriers, we developed a simple stepwise algorithm for navigating the PCSK9i approval process. Our algorithm can help relieve busy providers of heavy administrative burdens and facilitate greater accuracy, standardization, and efficiency in documentation.",
keywords = "Alirocumab (Praluent), Atherosclerotic cardiovascular disease (ASCVD), Evolocumab (Repatha), Familial hypercholesterolemia (FH), Low-density lipoprotein cholesterol (LDL-C), Prior authorization",
author = "Thomas Knickelbine and Lori Jia and White, {Susan K.} and Garberich, {Ross F.} and Oberembt, {Sandra J.} and Samantha Wills and Miedema, {Michael D.} and Brilakis, {Emmanouil S}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jacl.2019.01.005",
language = "English (US)",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - A systematic approach for successful PCSK9 inhibitor prescribing in clinical practice

AU - Knickelbine, Thomas

AU - Jia, Lori

AU - White, Susan K.

AU - Garberich, Ross F.

AU - Oberembt, Sandra J.

AU - Wills, Samantha

AU - Miedema, Michael D.

AU - Brilakis, Emmanouil S

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Despite patient and provider interest, the use of PCSK9i therapy remains limited in clinical practice. High annual listed prices have created intense payer scrutiny and frequent health plan denials, with national approval rates in the range of 30% to 40%. Objective: Our goal was to validate the strategies for increasing PCSK9i approval rates and to present a framework for successful PCSK9i prescribing in clinical practice. Methods: In Sept 2015, a systematic team-based approach was developed and implemented at our institution. The approach centered on a preventive team of 3 senior staff cardiologists, 1 nurse practitioner, 1 physician assistant, 1 care coordinator, 1 pharmacist, and 1 pharmacy technician. The team was responsible for gathering and compiling the required documents to support an approval, as well as collaborating with the in-house pharmacy to complete PA and appeals processes. Results: In the total study population, 141 (71.9%) were approved for PCSK9i therapy at first submission and 55 (28.1%) were rejected. Of those initially rejected, 48 (85.7%) appealed and all 48 who appealed (100.0%) were ultimately approved. The final coverage decision was 189 (96.4%) approved and 7 (3.6%) rejected. Conclusion: Our study highlights the presence of modifiable barriers in the PCSK9i approval process. Given the crucial role of health care teams in overcoming these modifiable barriers, we developed a simple stepwise algorithm for navigating the PCSK9i approval process. Our algorithm can help relieve busy providers of heavy administrative burdens and facilitate greater accuracy, standardization, and efficiency in documentation.

AB - Background: Despite patient and provider interest, the use of PCSK9i therapy remains limited in clinical practice. High annual listed prices have created intense payer scrutiny and frequent health plan denials, with national approval rates in the range of 30% to 40%. Objective: Our goal was to validate the strategies for increasing PCSK9i approval rates and to present a framework for successful PCSK9i prescribing in clinical practice. Methods: In Sept 2015, a systematic team-based approach was developed and implemented at our institution. The approach centered on a preventive team of 3 senior staff cardiologists, 1 nurse practitioner, 1 physician assistant, 1 care coordinator, 1 pharmacist, and 1 pharmacy technician. The team was responsible for gathering and compiling the required documents to support an approval, as well as collaborating with the in-house pharmacy to complete PA and appeals processes. Results: In the total study population, 141 (71.9%) were approved for PCSK9i therapy at first submission and 55 (28.1%) were rejected. Of those initially rejected, 48 (85.7%) appealed and all 48 who appealed (100.0%) were ultimately approved. The final coverage decision was 189 (96.4%) approved and 7 (3.6%) rejected. Conclusion: Our study highlights the presence of modifiable barriers in the PCSK9i approval process. Given the crucial role of health care teams in overcoming these modifiable barriers, we developed a simple stepwise algorithm for navigating the PCSK9i approval process. Our algorithm can help relieve busy providers of heavy administrative burdens and facilitate greater accuracy, standardization, and efficiency in documentation.

KW - Alirocumab (Praluent)

KW - Atherosclerotic cardiovascular disease (ASCVD)

KW - Evolocumab (Repatha)

KW - Familial hypercholesterolemia (FH)

KW - Low-density lipoprotein cholesterol (LDL-C)

KW - Prior authorization

UR - http://www.scopus.com/inward/record.url?scp=85061092065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061092065&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2019.01.005

DO - 10.1016/j.jacl.2019.01.005

M3 - Article

C2 - 30745203

AN - SCOPUS:85061092065

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

SN - 1933-2874

ER -